Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

doi:10.1016/j.ejca.2024.114182

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2024

Felip Enriqueta, Metro Giulio, Soo Ross A, Wolf Jürgen, Solomon Benjamin J, Tan Daniel Sw, Ardizzoni Andrea, Lee Dae Ho, Sequist Lecia V, Barlesi Fabrice, Ponce-Aix Santiago, Abreu Delvys Rodriguez, Campelo Maria Rosario Garcia, Sprauten Mette, Djentuh Leslie O'Sullivan, Smith Nathalie, Jary Aline, Belli Riccardo, Glaser Sabine, Zou Mike, Cui Xiaoming, Giovannini Monica, Yang James Chih-Hsin

Abstract excerpt

PURPOSE: This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). METHODS: In phase 1b, patients with progression on first-/second-generation EGFR-TKIs received escalating doses of capmatinib 200-400 mg bid plus nazartinib 50-150 mg qd. Once the MTD/RP2D was declared, phase 2 commenced with patient enrollment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Imidazoles

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Triazines

Source

Open in PubMed

Identifiers

PMID: 38986421
DOI: 10.1016/j.ejca.2024.114182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.PMID 38986421Read ↗

Capmatinib for non-small cell lung cancer.Semantic proximity Read ↗

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Clinical efficacy and safety of nazartinib for epidermal growth factor receptor mutated non-small cell lung cancer: Study protocol for a prospective, multicenter, open-label.Semantic proximity Read ↗

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.Semantic proximity Read ↗

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studySemantic proximity Read ↗

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.Semantic proximity Read ↗

Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.Semantic proximity Read ↗

Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts.Semantic proximity Read ↗

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.Semantic proximity Read ↗

Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.